Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of talquetamab combinations versus investigator's choice in relapsed or refractory multiple myeloma
MOH_2023-10-31_013017Phase 3Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of talquetamab, teclistamab, pomalidomide, elotuzumab, bortezomib and 1 more in multiple myeloma (MM) (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Progression-related efficacy outcome. Started Sep 2023; status: active, not recruiting.
02
Drugs
talquetamabteclistamabpomalidomideelotuzumabbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-10-31_013017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-31_013017.